A forum for researchers, students and applicants in the field of cyclodextrin technology
A multi-year scientific collaboration between Brasilian and American scientists from Federal University at Rio de Janeiro, Brazil, Laboratory of Immunoregulation,
The researchers of TEVA (USA) explored the role of 2-hydroxypropyl-β-cyclodextrin (HPβCD) as an excipient in liquid formulations by evaluating its
Dementia is a progressive and irreversible deterioration in cognition that has a significant impact on the person’s activities of daily
Atherosclerosis (AS) has been considered a systemic disease characterized by the excessive generation of reactive oxygen species (ROS) and the
This study utilized a four-stage rational formulation development approach to mitigate aggregation and stabilize a high molecular weight protein, rhNELL-1.
In a recent study, Professors Bodor and Buchwald review the use of cyclodextrin-enabled formulations to develop oral tablets of cladribine
The central nervous system ( CNS) is increasingly recognized as a cholesterol-rich organ. While the brain accounts for approximately 5%
JIC Venture Growth Investments (VGI) announced that it has invested in Beren Therapeutics P.B.C. (“Beren Therapeutics”). Beren Therapeutics is developing
All these studies utilize the high solubilizing effect of 2,6-di-O-methyl beta-cyclodextrin studying various model drugs. The compatibility, inclusion stability, and
Pediatric drug development faces notable challenges due to age-related physiological differences, with limited approved formulations often leading to off-label or
